SRR599486
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.513
- INTERFERON_GAMMA_RESPONSE+0.388
- INFLAMMATORY_RESPONSE+0.300
- IL2_STAT5_SIGNALING+0.298
- ALLOGRAFT_REJECTION+0.275
- ANGIOGENESIS+0.274
- IL6_JAK_STAT3_SIGNALING+0.265
- BILE_ACID_METABOLISM+0.234
- COMPLEMENT+0.231
- HEME_METABOLISM+0.211
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.424
- HEDGEHOG_SIGNALING-0.396
- MYC_TARGETS_V2-0.312
- UNFOLDED_PROTEIN_RESPONSE-0.201
- OXIDATIVE_PHOSPHORYLATION-0.185
- NOTCH_SIGNALING-0.168
- UV_RESPONSE_DN-0.168
- DNA_REPAIR-0.157
- SPERMATOGENESIS-0.155
- E2F_TARGETS-0.111
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1429244 | GTEX | — | 0.917 |
| 2 | SRR1488172 | GTEX | — | 0.886 |
| 3 | SRR661925 | GTEX | — | 0.871 |
| 4 | SRR1350525 | GTEX | — | 0.866 |
| 5 | SRR603397 | GTEX | — | 0.866 |
| 6 | SRR1340133 | GTEX | — | 0.861 |
| 7 | SRR1475609 | GTEX | — | 0.861 |
| 8 | SRR612311 | GTEX | — | 0.856 |
| 9 | SRR1446828 | GTEX | — | 0.851 |
| 10 | SRR1092706 | GTEX | — | 0.849 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.513 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.388 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.298 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.275 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.274 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.265 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.234 | Inavolisib | — uncovered |
| COMPLEMENT | 0.231 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.211 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.211 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.196 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.189 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.182 | Idelalisib | — uncovered |
| COAGULATION | 0.178 | Binimetinib | — uncovered |
| PEROXISOME | 0.163 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.161 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.152 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.144 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |